Bioequivalency Study of Clarithromycin Tablets Under Fed Conditions
Status:
Completed
Trial end date:
2003-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a potential generic 500 mg
clarithromycin tablet formulation compared with Abbott Laboratories 500 mg clarithromycin
tablet, Biaxin® following a single 500 mg dose, administered with food.